Jimenez-Vicente C, Martinez-Roca A, Pomares H, Castano-Diez S, et al. Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF. Leuk Res 2023;135:107403.
PMID: 37837718